Welcome Address
Chair: E. Stratikos (GR)
12.30-13.00 Exploiting the role of NK cells in cancer immunotherapy R. Solana (ES)
13.00-13.30 MDSC and immune evasion G. Pawelec (DE)
13.30-14.00 The role of antigen processing and presentation in the immunogenicity of cancer E. Stratikos (GR)
14.00-14.30 The role of B lymphocytes in solid tumours: opportunities for antibody immunotherapy S. Karagianni (GR)
14.30-14.50 Q&A
Chair: J. Wischhusen (DE)
14.50-15.20 Biomarkers as a tool for precision immuno-oncology: the prostate cancer paradigm M. Adamaki (GR)
15.20-15.50 Immune gene signatures as predictive/prognostic biomarkers for prostate cancer M. Goulielmaki (GR)
15.50-16.20 Cancer gene signatures predicting clinical outcomes during Immune checkpoint blockade D. Speiser (DE)
16.20-16.50 The emergence role of liquid biopsy in the era of cancer immunotherapy E. Lianidou (GR)
16.50-17.10 Q&A
Coffee Break
Chair: C.N. Baxevanis (GR)
17.30-18.00 Update of the role of immunotherapy in Melanoma J. Duran Moreno (GR)
18.00-18.30 Τhe introduction of immunotherapy in the treatment of non-melanocyte skin cancers V. Papadopoulos (GR)
sponsored by Sanofi Genzyme
18.30-19.00 Head and neck carcinoma A. Psyrri (GR)
19.00-19.15 Q&A
Speaker: M. Liontos (GR)
Chair: A. Kotsakis (GR)
Q&A
Speaker: T. Whiteside (US)
Chair: A. Kotsakis (GR)
20:35-21:00 Q&A
Chair: C.N. Baxevanis (GR)
11.00-11.30 Mechanisms of immune resistance J. Wischhusen (DE)
11.30-12.00 miRNA - based regulation of tumor evolution B. Seliger (DE)
12.00-12.30 Immune activation strategies to achieve in situ tumor vaccination G. Adema (NL)
12.30-13.00 The host & microbiome crosstalk and its impact on tumorigenesis T. Frisan (SE)
13.00-13.20 Q&A
Speaker: M. Koukourakis (GR)
Chair: C.N. Baxevanis (GR)
Q&A
Light Lunch
Chair: C.N. Baxevanis (GR)
15.00-15.30 Distinct immune signatures correlate with prognostication, treatment responses and MRD status in Multiple Myeloma I. Kostopoulos (GR)
15.30-16.00 Non-coding RNAs: Role and clinical utility in cancer immunity and immunotherapy M. Avgeris (GR)
16.00-16.15 Q&A
Chair: C.N. Baxevanis (GR)
16.15-16.45 The intratumoral immune landscape in breast cancer A. Giatromanolaki (GR)
16.45-17.15 Cellular composition and dynamic interactions intratumorally P. Foukas (GR)
17.15-17.45 Novel aspects for the intratumoral immune cellular compartmentalization in pancreatic cancer I. Pateras (GR)
17.45-18.15 The tumor microenvironment and mechanistic pathways for immune checkpoint blockade efficacy P. Verginis (GR)
18.15-18.30 Q&Α
Coffee Break
Chair: A Kotsakis (GR)
18.50-19.20 Latest data on monotherapy in the 1st line of NSCLC K. Tsapakidis (GR)
sponsored by Sanofi Genzyme
19.20-19.50 Non small cell lung cancer D. Papadatos-Pastos (UK)
19.50-20.20 Small cell lung cancer D. Ziogas (GR)
20.20-20.30 Q&A
Speaker: S. Fortis (GR)
Chair: I.S. Pateras (GR)
21.00-21.30 Q&A
Chair: R. Tsitsilonis (GR)
11.00-11.30 Bispecific antibodies
11.30-12.00 Aspects of CD4+ T cell - based therapies for cancer E. Inderberg (NO)
12.00-12.30 Dendritic-cell based immunotherapy of ovarian cancer: results from phase II clinical trial J. Bartunkova (CZE)
12.30-12.45 Q&A
Speaker: A. Madrigal (UK)
Chair: R. Tsitsilonis (GR)
Q&A
Light Lunch
Chairs: V. Georgoulias (GR), A. Kotsakis (GR)
14.20-14.50 Urothelial carcinoma G.Tsironis (CY)
14.50-15.20 Breast carcinoma A. Matikas (SE)
15.20-15.50 The role of Immunotherapy in Gastrointestinal Tumors P. Papanastasopoulos (GR)
15.50-16.20 The State of the Art of Immunotherapy in Renal Carcinomas G. Lainakis (GR)
16.20-16.40 Q&A
Coffee Break
Chair: C.N. Baxevanis (GR)
17.00-17.30 Novel vaccine for breast cancer L. Conti (IT)
17.30-18.00 TCR-gene modified T cells for cancer immunotherapy M. Nishimura (US)
18.00-18.10 Q&A
Speaker: A. Koumarianou (GR)
Chair: A. Kotsakis (GR)
Q&A
A. Madrigal (UK), J. Wischhusen (DE), B. Seliger (DE)